NCT03454048View on ClinicalTrials.gov

Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 7, 2018

Primary Completion Date

November 1, 2018

Study Completion Date

November 20, 2018

Conditions
Malaria,FalciparumGametocytesControlled Human Malaria InfectionTransmission
Interventions
DRUG

Piperaquine (low dose)

subcurative regimen (480 mg)

DRUG

Piperaquine (high dose)

Curative regimen (960mg)

DRUG

Sulfadoxine pyrimethamine

Curative regimen (1000mg/50mg)

DRUG

Atovaquone Proguanil

Curative regimen (1000/400 mg, for 3 days)

OTHER

malaria challenge infection, P. falciparum 3D7

malaria challenge infection by P. falciparum 3D7-infected mosquito bites

OTHER

Blood stage malaria challenge infection, P. falciparum 3D7

P. falciparum 3D7-infected human erythrocytes administered intravenously for the purpose controlled human malaria infection.

Trial Locations (1)

6525 GA

Radboud university medical center, Nijmegen

All Listed Sponsors
collaborator

The PATH Malaria Vaccine Initiative (MVI)

OTHER

collaborator

QIMR Berghofer Medical Research Institute

OTHER

lead

Radboud University Medical Center

OTHER

NCT03454048 - Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2 | Biotech Hunter | Biotech Hunter